Non-Small Cell Lung Cancer

Boswellia has strong preclinical relevance in non-small cell lung cancer, with two especially important themes: cisplatin sensitisation and radioresistance reversal.

Overview

The NSCLC literature includes cell-cycle arrest, apoptosis, autophagy suppression, platinum sensitisation, and epigenetic effects on radiation resistance.

Key preclinical data

• AKBA causes G1/G0 arrest and apoptosis in NSCLC cells

• Suppresses autophagy survival pathways

• Sensitises NSCLC to cisplatin in preclinical work

• Reverses radiotherapy resistance via maspin methylation and AKT/FOXO1/p21-axis regulation

Clinical positioning

This is still preclinical, but it is one of the more clinically interesting Boswellia areas because both platinum resistance and radioresistance matter in real treatment settings.

References

AKBA exerts anti-cancer effects via cell cycle arrest, apoptosis induction and autophagy suppression in NSCLC
https://pmc.ncbi.nlm.nih.gov/articles/PMC6986255/

AKBA inhibits radiotherapy resistance in lung cancer by inhibiting maspin methylation and regulating the AKT/FOXO1/p21 axis
https://pmc.ncbi.nlm.nih.gov/articles/PMC12182535/

Jump to another Boswellia page

Core pages

• Boswellia in Oncology Overview

• Evidence Summary

• Anticancer Mechanisms

• Boswellia Evidence by Cancer Type

Mechanism deep dives

• Redox Dual Action

• NRF2 Impact

• Ferroptosis Findings

• Immune Effects

Practical pages

• Pharmacokinetics & Metabolism

• Safety & Interactions

• Synergistic Combinations

• Hydroxychloroquine + Boswellia

• Dosing & Timing

• Sourcing Quality Boswellia

Cancer-type pages

• Glioblastoma & Brain Tumours

• Breast Cancer

• Colorectal Cancer

• Pancreatic Cancer

• Prostate Cancer

• Non-Small Cell Lung Cancer

• Ovarian Cancer

• Other Cancer Types